ERBB2 and gastric cancer: Furthermore, even if the target is similar, when two different epitopes of HER2 were targeted on human gastric cancer cells using trastuzumab-IR700 (against domain IV of HER2) and pertuzumab-IR700 (against domain II of HER2), the combination NIR-PIT demonstrated synergy in a HER2-expressing xenograft model [68].